Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 5/20 | 0.35 |
| ▸ | ERN1 | O75460 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23839866 | 1.00 | TGM2 (0.36) | TGM2ALDH1A1ACHEERN1BRD4 | |
| SCHEMBL15631792 | 0.89 | TGM2 (0.43) | TGM2FOLH1CASP1 | |
| SCHEMBL16174189 | 0.82 | ACHE (0.42) | ACHEFOLH1 | |
| SCHEMBL14962055 | 0.82 | ACHE (0.37) | ALDH1A1ACHEERN1BRD4CASP1 | |
| SCHEMBL23705401 | 0.79 | TGM2 (0.52) | TGM2FOLH1CASP1 | |
| SCHEMBL23705400 | 0.79 | TGM2 (0.52) | TGM2FOLH1CASP1 | |
| SCHEMBL19414915 | 0.79 | TDP1 (0.36) | TGM2ACHEERN1BRD4 | |
| SCHEMBL3676772 | 0.78 | TGM2 (0.46) | TGM2ACHEERN1 | |
| SCHEMBL24173419 | 0.78 | ERN1 (0.37) | TGM2ERN1BRD4FOLH1CASP1 | |
| SCHEMBL24023996 | 0.77 | TGM2 (0.37) | TGM2ACHEERN1BRD4CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-09-21 | — | — | US | disclosed |
| WO-2021186166-A1 | GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021186169-A1 | ORAL GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | GLP1R, GIPR, NPY4R | TGM2 499/4885ALDH1A1 4025/4885ACHE 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.